[A22-39] Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Last updated 15.09.2022
Project no.:
A22-39
Commission:
Commission awarded on 31.03.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Indication:
Adults with symptomatic chronic heart failure with preserved ejection fraction
Result of dossier assessment:
- Without type 2 diabetes mellitus and without chronic kidney disease or with/without type 2 diabetes mellitus and with chronic kidney disease: hint of non-quantifiable added benefit
- With type 2 diabetes mellitus and without chronic kidney disease: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-93 | Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-12 | Empagliflozin - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-26 | Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A22-86 | Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39 | Commission completed |
| A23-142 | Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-78 | Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-09-05 A G-BA decision was published.